When Bismuth Quadruple Therapy Fails: Next-Step H. pylori Eradication in Autoimmune Gastritis with True Penicillin Allergy
Clinical scenario
This protocol applies to patients with autoimmune metaplastic atrophic gastritis (autoimmune gastritis) who have active Helicobacter pylori infection and a confirmed true penicillin allergy, and whose prior first-line eradication attempt has not achieved cure.
Unresolved H. pylori infection in autoimmune gastritis carries implications for cancer risk and can exacerbate nutritional deficiencies; eradication remains a clinical priority even after initial treatment failure.
Previous treatment & failure condition
Prior therapy did not achieve eradication
The first-line regimen attempted was bismuth quadruple therapy (BQT) — the only first-line option considered suitable for patients with a true penicillin allergy. Escalation to this salvage protocol is triggered when a test of cure, performed at least 4 weeks after completing BQT, remains positive for H. pylori.
Salvage approach (partial overview)
A levofloxacin-based salvage regimen is considered in patients with confirmed susceptibility to levofloxacin. Because of the true penicillin allergy, the combination is specifically modified — a penicillin-containing agent is replaced by an alternative agent. The complete regimen, all components, and the precise modification for penicillin allergy are detailed in the full protocol.
Dosing, duration, selection criteria, and sequencing remain in the full protocol below.
Treatment goal
Eradication of H. pylori infection, confirmed by a negative test of cure — urea breath test, fecal antigen test, or biopsy-based test — performed at least 4 weeks after completion of therapy.
References
DOI: 10.14309/ajg.0000000000002968
- Given the implications of potentially undiagnosed H. pylori infection for cancer risk and exacerbating nutritional deficiencies (e.g., iron deficiency), H. pylori testing and treatment in all patients diagnosed with AIG are recommended.
- Of the recommended and suggested options for treatment-naive patients, only optimized BQT is suitable for patients with a true penicillin allergy.
- In treatment-experienced patients with persistent H. pylori infection, levofloxacin triple therapy is suggested in patients with known levofloxacin-sensitive H. pylori strains and when optimized bismuth quadruple or rifabutin triple therapies have previously been used or are unavailable (conditional recommendation, low quality of evidence).
- Metronidazole should be used in place of amoxicillin for levofloxacin triple therapy in patients with true penicillin allergy.
- All patients who are treated for H. pylori infection should undergo a test of cure with an appropriately conducted urea breath test, fecal antigen test, or biopsy-based test at least 4 weeks after completion of therapy.
View source ↗